Nurix Therapeutics Presents Updated Positive Data Demonstrating Durable, Deepening Responses in Ongoing Clinical Trial of Bexobrutideg (NX-5948) Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Waldenström
Provided By GlobeNewswire
Last update: Jun 12, 2025
Complete response achieved in CLL; overall objective response rate of 80.9% in CLL patients and 84.2% in patients with WM
Bexobrutideg was well tolerated with no new safety signals observed with longer duration on study or higher doses
Read more at globenewswire.com10.63
+0.21 (+2.02%)
Find more stocks in the Stock Screener
NRIX Latest News and Analysis
14 days ago - By: Chartmill
